Inclusion Criteria:

          -  Evidence of a response (partial response or better based on investigator's
             determination of response by International Myeloma Working Group [IMWG] criteria) to
             daratumumab-containing intravenously (IV) therapy with response duration of at least 4
             months

          -  Participants must have progressed from or be refractory to their last line of
             treatment. Relapsed or refractory disease as defined as: a) Relapsed disease is
             defined as an initial response to previous treatment, followed by confirmed
             progressive disease (PD) by IMWG criteria greater than (>) 60 days after cessation of
             treatment. b) Refractory disease is defined as less than (<) 25 percent (%) reduction
             in M-protein or confirmed PD by IMWG criteria during previous treatment or >60 days
             after cessation of treatment

          -  Received 1 or 2 prior line(s) of treatment of which one contained Dara IV, and
             completed Dara IV at least 3 months prior to randomization. A single line of therapy
             may consist of 1 or more agents, and may include induction, hematopoietic stem cell
             transplantation, and maintenance therapy. Radiotherapy, bisphosphonate, or a single
             short course of corticosteroids (no more than the equivalent of dexamethasone 40
             milligram per day [mg/day] for 4 days) would not be considered prior lines of therapy

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0, 1, or 2

          -  Women of childbearing potential must have a negative urine or serum pregnancy test at
             screening within 14 days prior to randomization

        Exclusion Criteria:

          -  Previous treatment with daratumumab within the last 3 months prior to randomization

          -  Discontinuation of Dara IV due to a daratumumab-related adverse event (AE)

          -  History of malignancy (other than multiple myeloma) unless all treatment of that
             malignancy was completed at least 2 years before consent and the patient has no
             evidence of disease. Further exceptions are squamous and basal cell carcinomas of the
             skin and carcinoma in situ of the cervix, or breast, or other non-invasive lesion,
             that in the opinion of the investigator, with concurrence with the sponsor's medical
             monitor, is considered cured with minimal risk of recurrence within 3 years

          -  Allergies, hypersensitivity, or intolerance to daratumumab, hyaluronidase, monoclonal
             antibodies (mAbs), human proteins, or their excipients, or known sensitivity to
             mammalian-derived products. Known history of allergy to Captisol (a cyclodextrin
             derivative used to solubilize carfilzomib)

          -  Participant is: a) Known to be seropositive for human immunodeficiency virus. b)
             Seropositive for hepatitis B (defined by a positive test for hepatitis B surface
             antigen [HBsAg]). Participants with resolved infection (example: participants who are
             HBsAg negative but positive for antibodies to hepatitis B core antigen [anti-HBc]
             and/or antibodies to hepatitis B surface antigen [anti-HBs]) must be screened using
             real-time polymerase chain reaction (PCR) measurement of hepatitis B virus (HBV)
             deoxyribonucleic acid (DNA) levels. Those who are PCR positive will be excluded. c)
             Known to be seropositive for hepatitis C (except in the setting of a sustained
             virologic response [SVR], defined as aviremia at least 12 weeks after completion of
             antiviral therapy)